Literature DB >> 16283137

[Therapeutic options of chronic constipation].

H Krammer1, F Schlieger, M V Singer.   

Abstract

Chronic constipation is a widespread disease affecting up to 25 percent of the population in western countries. The symptoms associated with constipation may lead to a heavy burden and a decrease in quality of life. The therapy of chronic constipation is based upon its type and severity. Patients with normal transit may benefit from lifestyle measures including dietetic advice. However, almost none of these measures has been validated in a controlled trial. Bulk forming laxatives such as psyllium seeds and probiotics have a moderate evidence (Grade B). In certain cases, the use of osmotic laxatives, e. g. polyethylene glycol solutions (Grade A), is necessary. Tegaserod, a selective agonist of the serotonine subtype 4 (5-HT(4)), has a good evidence to treat constipation (Grade A). Patients with slow-transit constipation (transit-time over 72 hours) are dependent on osmotic (polyethylene glycol solutions, Grade A) and stimulant laxatives (bisacodyl, Grade C). Patients who suffer from defecatory disorders (outlet constipation) should be treated with bulk forming laxatives (Grade B) together with suppositories (e. g. CO(2)-suppositories) and enemas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283137     DOI: 10.1007/s00108-005-1509-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

Review 1.  [Dietary fiber in the therapy of constipation].

Authors:  R Schäfer
Journal:  Z Gastroenterol       Date:  2000-06       Impact factor: 2.000

2.  [The epidemiology of constipation].

Authors:  J F Erckenbrecht
Journal:  Z Gastroenterol       Date:  2000-06       Impact factor: 2.000

3.  [Probiotics as therapeutic agents in irritable bowel syndrome].

Authors:  H-J Krammer; F Schlieger; H Harder; A Franke; M V Singer
Journal:  Z Gastroenterol       Date:  2005-05       Impact factor: 2.000

Review 4.  Functional bowel disorders and functional abdominal pain.

Authors:  W G Thompson; G F Longstreth; D A Drossman; K W Heaton; E J Irvine; S A Müller-Lissner
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

5.  Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation.

Authors:  A Attar; M Lémann; A Ferguson; M Halphen; M C Boutron; B Flourié; E Alix; M Salmeron; F Guillemot; S Chaussade; A M Ménard; J Moreau; G Naudin; M Barthet
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

6.  A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative.

Authors:  J A DiPalma; P H DeRidder; R C Orlando; B E Kolts; M B Cleveland
Journal:  Am J Gastroenterol       Date:  2000-02       Impact factor: 10.864

7.  Effect of bisacodyl on intestinal electrolyte and water net transport and transit. Perfusion studies in men.

Authors:  K Ewe
Journal:  Digestion       Date:  1987       Impact factor: 3.216

Review 8.  Myths and misconceptions about chronic constipation.

Authors:  Stefan A Müller-Lissner; Michael A Kamm; Carmelo Scarpignato; Arnold Wald
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

9.  [Mode of action of bisacodyl (dulcolax) on isolated muscles of human colon (author's transl)].

Authors:  P Mitznegg; E Schubert; W Domschke; U Strunz; S Domschke; K Schwemmle; L Demling; F Heim
Journal:  Klin Wochenschr       Date:  1975-05-15

10.  Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation.

Authors:  E Corazziari; D Badiali; G Bazzocchi; G Bassotti; P Roselli; G Mastropaolo; M G Lucà; R Galeazzi; E Peruzzi
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

View more
  1 in total

1.  Effects of nociceptin/orphanin FQ on rats with cathartic colon.

Authors:  Hai-Yan Li; Xiang Yan; Quan-Lai Xue; Yong-Ning Zhou; Yan Gao; Rui Wang; Yong-Ming Liu; Jun-Tao Ran
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.